Please login to the form below

Not currently logged in
Email:
Password:

Two new senior hires announced at Ashfield

Gregg Flynn and Colin Stanley will serve as global presidents

Ashfield has announced the promotion of Greg Flynn to president of Ashfield Commercial and Patient Solutions and the appointment of Colin Stanley as president of Ashfield Advisory.Greg Flynn

Flynn (pictured left) has nearly 25 years of experience working in the pharmaceutical service and manufacturer sectors in Europe, the US and Asia.

He takes the helm as president from his most recent role at Ashfield – part of UDG Healthcare – of chief operating officer and North American regional president for Ashfield Commercial and Patient Solutions.

Flynn spent the first 12 years of his career working across a number of leadership positions at pharmaceutical companies in the UK.

After spending time within the UK business at Ashfield, he relocated to the US in 2010, and after a successful period there went on to spend five years in Japan.

While in Japan, he established and grew the Ashfield CMIC business into a market leadership position. He moved back to the US in 2017 to take up his president role.Colin Stanley

Stanley (pictured right) joins Ashfield from ICON, where his most recent role was president of ICON Functional Services and member of its executive leadership team.

He has more than 22 years of experience working in the contract research organisation industry.

Prior to his president role at ICON, he held a number of roles at the company including chief operating officer of DOCS, and vice president of clinical operations for the Asia Pacific.

Stanley will bring extensive operational, functional and geographic expertise to Ashfield's advisory businesses.

4th December 2019

From: Marketing

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics